This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas N. Chase, MD; Larry K. Y. Ng, MD

Arch Neurol. 1972;27(6):486-491.

Abstract
Basal concentrations and probenecid-induced accumulations of homovanillic acid (HVA), a major metabolite of dopamine, in the lumbar cerebrospinal fluid (CSF) of parkinsonian patients were markedly below those of control subjects. Although steady state levels of 5-hydroxyindoleacetic acid (5-HIAA) did not differ significantly from control values, there was a substantial diminution in the response of this serotonin metabolite to probenecid. Since probenecid inhibits the clearance of HVA and 5-HIAA from CSF, these results suggest that a concomitant reduction in the central metabolism of serotonin and dopamine attends clinically advanced Parkinson's disease. Pretreatment severity of parkinsonian rigidity and bradykinesia, but not tremor, correlated inversely with the probenecid-induced rise in both monoamine metabolites. There was, however, no apparent association between the therapeutic response to levodopa and either the severity of parkinsonian signs prior to therapy or the magnitude of the defect in monoamine metabolism.

Author Affiliations
Bethesda, Md

From the Neurology Unit, National Institute of Mental Health, Bethesda, Md.

Footnotes
Accepted for publication June 16, 1972.

Reprint requests to Neurology Unit, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, Md 20014 (Dr. Chase).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reaction Time and Vigilance in Parkinson's Disease: Possible Role of Altered Norepinephrine Metabolism
Stern et al.
Arch Neurol 1984;41:1086-1089.
ABSTRACT  

Paradoxical Response to Dopaminergic Agents in Parkinsonism
Weiner et al.
Arch Neurol 1978;35:453-455.
ABSTRACT  

Juvenile Parkinsonism Treated With Levodopa
Sachdev et al.
Arch Neurol 1977;34:244-245.
ABSTRACT  

Fenfluramine Hydrochloride Treatment of Parkinsonism
Beasley et al.
Arch Neurol 1977;34:255-256.
ABSTRACT  

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist
Chase et al.
Arch Neurol 1974;30:383-386.
ABSTRACT  

Central Monoamine Metabolism in Man: Effect of Putative Dopamine Receptor Agonists and Antagonists
Chase
Arch Neurol 1973;29:349-351.
ABSTRACT  

Adenosine 3', 5'-Monophosphate in Cerebrospinal Fluid: Effect of Drugs and Neurologic Disease
Cramer et al.
Arch Neurol 1973;29:197-199.
ABSTRACT